New drug combo targets tough lung cancer mutation
NCT ID NCT06816992
First seen Apr 24, 2026 · Last updated Jun 21, 2026 · Updated 12 times
Summary
This early-stage trial tests a new oral drug called ORIC-114 combined with an injectable drug, amivantamab, in people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The study aims to find the safest dose and see if the combination shrinks tumors. About 76 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
Peter MacCallum Cancer Centre
NOT_YET_RECRUITINGMelbourne, Victoria, 03000, Australia
-
The Princess Margaret Hospital
NOT_YET_RECRUITINGToronto, Ontario, M5G 1Z5, Canada
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ORIC-114 (oral drug) plus amivantamab (injectable drug)
What this could lead to
If this combination works, it could offer a new treatment option for people with a hard-to-treat form of lung cancer that has specific genetic changes.
What could go wrong
This is an early Phase 1b trial with only 76 participants, so the main goal is safety and dosing, not proof of effectiveness. The combination may cause side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.